BioFire Panels: One Test – Countless Benefits 

12 mins0
Post Views: 664

Empower your business with BioFire panels. From faster detection to better patient management, these tests help you deliver accurate, timely results – boosting trust, outcomes and your business potential.

Respiratory Panel 

22 Pathogens Detected 

This test uses Multiplex PCR from nasopharyngeal swab specimens. It enables rapid simultaneous detection of numerous viral and bacterial pathogens associated with upper respiratory tract infections. 

This assay identifies specific nucleic acid sequences. It facilitates faster and more accurate differential diagnosis and treatment decisions.  

One Patient | 22 Target In One Comprehensive Test | Improves Patient Management 

Superior Clinical & Economic Outcomes 

Studies show that the BioFire RP Panel has been shown to: 

  • Dramatically Reduce time to diagnosis 
  • Improve patient management 
  • Reduce unnecessary testing 
  • Reduce total cost of care and resource utilization 
  • Prevent exposure to unnecessary antibiotics 
  • Prevent secondary spread of infection 
  • Result in shorter hospital stays 
  • Provide more timely and effective treatment 
  • Detects more positives & co-infections than non-panel assays. 

Biofire® Respiratory 2.1 (RP2.1) Panel 

Sample type: Nasopharyngeal swab in transport media 

Test code: BIORP

Processed at: CPL 

TAT: 24 Hours  

Pathogens Covered 

Viruses: 

  • Adenovirus 
  • Coronavirus 229E 
  • Coronavirus HKU1
  • Coronavirus NL63 
  • Coronavirus OC43 
  • Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) 
  • Human Metapneumovirus 
  • Human Rhinovirus/Enterovirus 
  • Influenza A 
  • Influenza A/H1 
  • Influenza A/H1 – 2009 
  • Influenza A/H3
  • Influenza B
  • Parainfluenza Virus 1  
  • Parainfluenza Virus 2 
  • Parainfluenza Virus 3 
  • Parainfluenza Virus 4 
  • Respiratory Syncytial Virus 

Bacteria: 

  • Bordetella parapertussis 
  • Bordetella pertussis 
  • Chlamydia pneumoniae 
  • Mycoplasma pneumoniae 

BioFire RP2.1 Panel Performance 

Overall 

  • 97.4% Sensitivity 
  • 99.4% Specificity 

Go To Market 

  • ICU beds in 20-50 bedded hospitals & Critical Care Units 
  • Intensivist, Pediatric – NICU 
  • Immunocompromised patients

(Transplant patients, Oncology patients etc.) 

  • Pulmonologists 

Blood Culture® Identification Panel 

43 Targets 

The BioFire Blood Culture Identification (BCID) Panel is a multiplex PCR- based assay designed for the rapid and simultaneous detection of a broad spectrum of bacterial, fungal and antimicrobial resistance genes directly from positive blood culture samples. 

This test facilitates the expedited identification of causative pathogens in bloodstream infections (BSIs), including sepsis, a life-threatening condition characterized by dysregulated host response to infection. 

Who Should Get Tested? 

Positive blood cultures from adult and pediatric patients with monomicrobial or polymicrobial bloodstream infections. 

  • Children and adults 
  • Elderly Patients 
  • High risk patients: immuno-compromised or with co-morbidities 
  • Critically ill patients 

Timely & Accurate diagnosis leads to better BSI outcomes: 

  • Lessens unnecessary antibiotic use 
  • Improves time to anti-microbial de-escalation 
  • Decreases time to effective therapy   
  • Reduces hospital costs, including by reducing repeat blood cultures & length of stay

Biofire® Blood Culture Identification 2 (BCID2) Panel

Sample Type: Positive Blood Culture Sample 

Test Code: BIOBC 

Processed At: CPL 

TAT: 24 Hours 

Pathogens covered 

GRAM-NEGATIVE BACTERIA 

  • Acinetobacter calcoaceticusbaumannii complex 
  • Bacteroides fragilis 
  • Enterobacterals: 
  • Enterobacter cloacae complex 
  • Escherichia coli 
  • Klebsiella aerogenes
  • Klebsiella oxytoca 
  • Klebsiella pneumoniae group 
  • Proteus spp.
  • Salmonella spp.
  • Serratia marcescens 
  • Haemophilus influenzae 
  • Neisseria meningitidis 
  • Pseudomonas aeruginosa
  • Stenotrophomonas maltophilia 

GRAM – POSITIVE BACTERIA 

  • Enterococcus faecalis 
  • Enterococcus faecium 
  • Listeria monocytogenes 
  • Staphylococcus spp.                                      
  • Staphylococcus aureus 
  • Staphylococcus epidermidis 
  • Staphylococcus lugdunensis 
  • Streptococcus spp. 
  • Streptococcus agalactiae 
  • Streptococcus pneumoniae 
  • Streptococcus pyogenes 

YEAST 

  • Candida albicans 
  • Candida auris 
  • Candida glabrata 
  • Candida krusei 
  • Candida parapsilosis 
  • Candida tropicalis 
  • Cryptococcus 

(C. neoformans/ C. gattii) 

ANTIMICROBIAL RESISTANCE GENES 

Carbapenemases 

  • IMP 
  • KPC 
  • OXA-48-like 
  • NDM 
  • VIM 

Colistin Resistance 

  • mcr-1

ESBL 

  • CTX-M 

Methicillin Resistance

  • mecA/C
  • mecA/C and MREJ (MRSA)  

Vancomycin Resistance 

  • vanA/B

Go To Market 

  • ICU beds in 20-50 bedded hospitals & Critical Care Units 
  • Intensivist, Pediatric – NICU 
  • Immunocompromised patients 
  • (Transplant patients, Oncology patients etc.) 
  • Pulmonologists,
  • MD Medicine Doctors 

PNEUMONIA PANEL 

34 Targets 

The BioFire Pneumonia Panel uses multiplex PCR to detect a comprehensive array of bacterial, viral and fungal pathogens directly from lower respiratory tract specimens, including sputum, bronchoalveolar lavage (BAL) and endotracheal aspirates. 

This assay facilitates rapid identification of causative agents in pneumonia, enabling targeted microbial therapy and improved clinical management. It enhances diagnostic accuracy and reduces time to pathogens identification compared to traditional culture-based methods.

Significance 

Pneumonia patients require appropriate therapy quickly. 

Challenges in Pneumonia: 

  • Traditional culture methods are insensitive &  time consuming 
  • Initial antibiotic treatment fails in 1 to 5 community-acquired pneumonia patients, requiring an additional or different antibiotic course, an ER Visit or hospitalization.  

The right test, the first time: 

  • The BioFire FilmArray Pneumonia Panel plus gives sensitive, accurate results from a variety of commonly collected lower respiratory tract specimens. These fast, reliable results may allow clinicians to have confidence in making targeted therapy decisions. 
  • Detects more bacteria: PCR detects nucleic acids rather than only organisms that will grow on culture media, detecting many more bacteria than culture. 
  • Reports semi-quantative results: Provides relative abundance information for 15 bacteria that can be a pathogen or normal flora. 
  • It improves patient care by improving time to targeted therapy, reducing treatment cost and improving laboratory and patient management workflows.
  • It helps in Appropriate  Antimicrobial Stewardship.

Biofire-Pneumonia Plus Panel 

Sample Type: Bronchoaleveolar Lavage (BAL), Sputum, Endotracheal secretion (ETA) 

Test Code: BIOPP

Processed At: CPL 

TAT: 24 Hours 

Pathogens Covered  

Bacteria: 

  • Acinetobacter calcoaceticus baumannii complex 
  • Enterobacter cloacae complex 
  • Escherichia coli 
  • Haemophilus influenzae 
  • Klebsiella aerogenes 
  • Klebsiella oxytoca 
  • Klebsiella pneumoniae group 
  • Moraxella catarrhalis 
  • Proteus spp. 
  • Pseudomonas aeruginosa 
  • Serratia marcescens 
  • Staphylococcus aureus 
  • Streptococcus agalactiae 
  • Streptococcus pneumoniae 
  • Streptococcus pyogenes 

Atypical Bacteria: 

  • Chlamydia pneumoniae
  • Legionella pneumophila 
  • Mycoplasma pneumoniae 

Viruses:

  • Adenovirus 
  • Coronavirus 
  • Human Metapneumovirus 
  • Human Rhinovirus/ Enterovirus 
  • Influenza A 
  • Influenza B 
  • Middle East Respiratory Syndrome Coronavirus 
  • Parainfluenza Virus 
  • Respiratory Syncytial Virus 

Antimicrobial Resistance Genes: 

  • Methicillin Resistance 

mecA/C and MREJ 

Carbapenemases

  • IMP 
  • KPC 
  • NDM 
  • Oxa-48-like 
  • VIM 

ESBL 

  • CRX-M

Diseases Under Surveillance: 

  • Influenza-including influenza  A (H1N1)
  • Legionnaires’ disease 
  • Haemophilus influenzae 

Go To Market 

  • ICU beds in 20-50 bedded hospitals & critical care units 
  • Intensivist, Pediatric – NICU 
  • Immunocompromised patients 
  • (Transplant patients, Oncology patients etc.)
  • Pulmonologists, 
  • Patients undergoing Incubation/ Ventilation / Bronchioscopy  

Download Handouts Here:

Blood Culture: https://lead.thyrocare.com/wp-content/uploads/2025/07/Blood-Culture.pdf 

Pneumonia: https://lead.thyrocare.com/wp-content/uploads/2025/07/PNEUMONIA.pdf 

Respiratory Panel:  https://lead.thyrocare.com/wp-content/uploads/2025/07/Respiratory-Panel-1.pdf 

Combined Handout: https://lead.thyrocare.com/wp-content/uploads/2025/07/Biofire-Booklet_ctcv-2.pdf 

We hope you found this article helpful! Keep exploring Knowledge Base for the latest updates on tests, offers and more.

pankaj

Related Articles